Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06247163

PET-guided Radiotherapy for Patients With Small Cell Lung Cancer.

There is a prospective risk-adapted evaluation of the optimal dose of radiotherapy for definitive radiotherapy of locally advanced small cell lung cancer within the corridor recommended as standard therapy according to the current interdisciplinary S3 guideline of the German Cancer Society/Cancer Aid/AWMF

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Small Cell Lung Carcinoma Bronchial Neoplasms Carcinoma, Bronchogenic Lung Diseases Lung Neoplasms Neoplasms Neoplasms by Site Respiratory Tract Diseases Respiratory Tract Neoplasms Thoracic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

The main objective of this study is to determine whether patients with SCLC who have a metabolically active residual tumor in the fluorodeoxyglucose (FDG) PET/CT scan after two to three cycles of induction chemotherapy have a similarly low local recurrence rate with higher dose. There is a prospective risk-adapted evaluation of the optimal dose of radiotherapy for definitive radiotherapy of locally advanced small cell lung cancer within the corridor recommended as standard therapy according to the current interdisciplinary S3 guideline of the German Cancer Society/Cancer Aid/AWMF. Allocation to PET boost, if confirmed vital tumor rest by PET CT and biopsy.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Histopathologic confirmation
  • Limited disease

Exclusion criteria

  • Other histology than small cell lung cancer
  • Further tumor diagnosis
  • ECOG 3 or worse
  • Extensive disease
  • stage IV

Treatment and study plan

PET based Raditherapy boost

Radiation

An Interim PET CT will be performed. If there is residual vital tumor, a higher radiation dose will be applied.

Primary outcomes

  1. Local recurrence free survival

    Time frame: 2 months to 5 years

    Local recurrence free survival

  2. Distant recurrence free survival

    Time frame: 2 months to 5 years

    Distant recurrence free survival

  3. Overall survival

    Time frame: 2 months to 5 years

    Overall survival

Study contacts

Contact information is provided by the study sponsor or research team.

Maja Guberina

CONTACT

[email protected]

020172383121

Sponsors and collaborators

Lead sponsor

University Hospital, Essen

Other

Registry information

Official study title

Prospective PET-guided Radiotherapy for Patients With Small Cell Lung Cancer.

Acronym: PET-ART

Important dates

Study start
2024
Primary completion
2025
Study completion
2029
First posted
Feb 7, 2024
Registry last updated
Sep 27, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.